Stocks and Investing
Stocks and Investing
Wed, February 22, 2017
[ 07:47 AM ] - United States, WOPRAI
[ 07:47 AM ] - United States, WOPRAI
[ 07:47 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 01:46 AM ] - United States, WOPRAI
[ 01:46 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 01:45 AM ] - United States, WOPRAI
[ 12:45 AM ] - United States, WOPRAI
[ 12:45 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Jason Wittes Initiated (TGTX) at Strong Buy and Held Target at $26 on, Feb 22nd, 2017
Jason Wittes of Aegis Capital, Initiated "TG Therapeutics, Inc." (TGTX) at Strong Buy and Held Target at $26 on, Feb 22nd, 2017.
Jason, nor any peers, have made any analyst calls on TGTX in the last 4 months.
Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30
Contributing Sources